Latest news
25 items- PRAscentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive DirectorsROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
- INSIDERGu Ehong sold $7,513 worth of Ordinary Shares (1,731 units at $4.34) and returned $5,724 worth of Ordinary Shares to the company (17,889 units at $0.32), closing all direct ownership in the company (SEC Form 4)4 - LianBio (0001831283) (Issuer)
- SECSEC Form 15-12G filed by LianBio15-12G - LianBio (0001831283) (Filer)
- NEWSWhat's Going On With LianBio (LIAN) Stock?LianBio – ADR (NASDAQ:LIAN) shares are trading higher by some 84% to $0.35 Friday afternoon on continued volatility. The company in late February announced its intent to delist its American Depositary Shares (ADSs) from the Nasdaq Global Market. This decision, made following a strategic review by the Board of Directors, involves winding down operations and deregistering its ordinary shares and ADSs. The company aims to reduce costs associated with regulatory compliance and management time, while returning value to shareholders through asset sales, out-licensing efforts, and dividends. Trading of ADSs post-delisting is expected to shift to privately negotiated sales and potentially an ove
- SECSEC Form EFFECT filed by LianBioEFFECT - LianBio (0001831283) (Filer)
- SECSEC Form F-6 POS filed by LianBioF-6 POS - LianBio (0001831283) (Subject)
- SECSEC Form S-8 POS filed by LianBioS-8 POS - LianBio (0001831283) (Filer)
- SECSEC Form S-8 POS filed by LianBioS-8 POS - LianBio (0001831283) (Filer)
- SECSEC Form S-8 POS filed by LianBioS-8 POS - LianBio (0001831283) (Filer)
- SECSEC Form POS AM filed by LianBioPOS AM - LianBio (0001831283) (Filer)
- SECSEC Form 25 filed by LianBio25 - LianBio (0001831283) (Filer)
- 13D/GSEC Form SC 13D/A filed by LianBio (Amendment)SC 13D/A - LianBio (0001831283) (Subject)
- NEWSLianBio Reports Voluntarily Delisting From Nasdaq;LianBio expects to file a Form 25 with the SEC and Nasdaq relating to the voluntary delisting of its ADSs on or about March 11, 2024. As previously announced, the Company has initiated the wind down of its operations, including the voluntary delisting and deregistration of the company's ordinary shares and ADSs, following the completion of a comprehensive strategic review of the Company by the Board.
- PRLianBio Announces Voluntarily Delisting from NasdaqSHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its
- INSIDERPoukalov Konstantin exercised 36,300 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 19,218 units of Ordinary Shares (SEC Form 4)4 - LianBio (0001831283) (Issuer)
- INSIDERPerceptive Advisors Llc exercised 72,600 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 38,436 units of Ordinary Shares (SEC Form 4)4 - LianBio (0001831283) (Issuer)
- INSIDERStone Adam Leo exercised 36,300 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 19,218 units of Ordinary Shares (SEC Form 4)4 - LianBio (0001831283) (Issuer)
- INSIDERGianakakos Anastasios exercised 36,300 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 19,218 units of Ordinary Shares, increasing direct ownership by 47% to 53,630 units (SEC Form 4)4 - LianBio (0001831283) (Issuer)
- INSIDERSilbermann Susan Michele exercised 36,300 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 19,218 units of Ordinary Shares (SEC Form 4)4 - LianBio (0001831283) (Issuer)
- NEWSWhy IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionShares of IPG Photonics Corporation (NASDAQ:IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance. IPG Photonics posted GAAP earnings of 89 cents per share, versus market estimates of 95 cents per share. The company’s quarterly sales came in at $298.90 million versus expectations of $286.12 million. IPG Photonics shares dipped 11.2% to $92.06 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Ohmyhome Limited (NASDAQ:OMH) shares climbed 300% to $4.80. BioNexus Gene Lab Corp. (NASDAQ:BGLC) got a boost, surging 270% to $1.52. Digital Brands Group, Inc. (NASD
- NEWSLianBio shares are trading higher after the company completed its strategic review and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, delisting of ADS and workforce reductions. Also, the company declared a $4.80 special dividend.
- NEWSEcolab Posts Strong Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On TuesdayU.S. stocks were lower, with the Dow Jones index dipping more than 500 points on Tuesday. Shares of Ecolab Inc. (NYSE:ECL) rose during Tuesday’s session after the company reported better-than-expected fourth-quarter financial results and issued first-quarter adjusted EPS guidance above estimates. Ecolab posted adjusted earnings of $1.55 per share, beating market estimates of $1.54 per share. The company’s quarterly sales came in at $3.94 billion versus estimates of $3.93 billion, according to data from Benzinga Pro. Ecolab shares gained 6.4% to $216.00 on Tuesday. Here are some other big stocks recording gains in today’s session. Whole Earth Brands, Inc. (NASDAQ:FREE) gained 35.3% to
- NEWSLianBio Completes Strategic Review And Determined To Initiate The Wind Down Of Its Operations, Including Sale Of Remaining Pipeline Assets, Delisting Of ADSs And Workforce Reductions; Board Has Declared Special Dividend Of $4.80/Sharea
- SECLianBio filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - LianBio (0001831283) (Filer)
- PRLianBio Announces Completion of Strategic ReviewSHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities
LIAN FAQ
7 questionsWhat does LianBio do?
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric...Where does LIAN stock trade?
LianBio (LIAN) is listed on NASDAQ.What sector and industry is LIAN in?
LianBio operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did LianBio go public?
LianBio (LIAN) completed its IPO in 2021.What are analysts saying about LIAN?
LianBio has had 2 recent analyst actions on file. The most recent action was from BofA Securities: Underperform with a $300.00 price target on 2024-01-03. Recent price targets range from $300.00 to $400.00.What companies are similar to LIAN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare LIAN side-by-side with any of them on Quantisnow.How can I track LIAN on Quantisnow?
Quantisnow aggregates LianBio's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LIAN to receive live email and push alerts on every new disclosure.